Portage Biotech Inc., a clinical-stage immuno-oncology company focused on overcoming cancer treatment resistance, entered into an agreement with Merck.
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
